News & Updates

The selective, oral sodium–glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin reduces the risk of cardiovascular (CV) death or worsening heart failure (HF) in patients with HF and mildly reduced or preserved ejection fraction (HFmrEF or HFpEF) in the phase III DELIVER* trial, touted as the largest and most inclusive thus far in this patient group.

High adherence to the palaeolithic diet helps reduce sleep apnoea in menopausal women who are overweight, with the benefit linked to weight loss, according to a secondary analysis of a trial comparing a 2-year intervention of a palaeolithic diet with a low-fat control diet according to the Nordic Nutritional Recommendations.

Utilization of hearts donated after circulatory death (DCD) appears to result in transient post-transplant right heart dysfunction and short-term clinical outcomes otherwise comparable to transplantation using hearts donated after brain death (DBD), reveals a recent study.

Retreatment with infliximab (IFX) appears safe and effective in nearly a third of patients with Crohn’s disease (CD), independent of the reason for prior discontinuation, results of a study have shown.

Adjuvant therapy with 5-fluorouracil and low-molecular weight heparin (LMWH) is not superior to placebo in the prevention of proliferative vitreoretinopathy (PVR) in eyes with rhegmatogenous retinal detachment (RRD), reports a study.